Astragaloside IV ameliorates atherosclerosis by targeting TAK1 to suppress endothelial cell proinflammatory activation.

导出 LinkOut

翻译打印收藏纠错

作者： Shuang,Hua ^[1] ; Han,Zhang ^[1] ; Jixu,Li ^[1] ; Xiaonian,Zhou ^[1] ; Shujie,Zhang ^[1] ; Yao,Zhu ^[1] ; Xingqun,Yan ^[2] ; Ping,Gu ^[3] ; Zhe,Huang ^[4] ; Weimin,Jiang ^[5]

作者单位： Department of Cardiology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China. ^[1] Department of Genetics and Developmental Science, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China. ^[2] Department of Endocrinology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China; Southeast University, School of Medicine, Nanjing, China. Electronic address: guping@nju.edu.cn. ^[3] Department of Genetics and Developmental Science, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China; Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China; Department of Cardiology, Shanghai Pudong New Area People's Hospital, Shanghai, China. Electronic address: zhehuang@sjtu.edu.cn. ^[4] Department of Cardiology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China. Electronic address: jwm0410@njucm.edu.cn. ^[5]

关键词 Astragaloside IV Atherosclerosis Endothelial cell MAPK TAK1